Activity: about 64 hours
Classification: Human chorionic gonadotropin (injectionis)
Dosages: Male 500-10000 IU / week
Water Retention: Yes
High blood pressure: Yes
Aromatization: Actually hCG aromatizing, but with increasing lumigan eyelashes testosterone aromatization possible
COMPOSITION AND PACKAGING:
long. d / f in. r-ra 5000 IU amp. with sol. in amp. 1 ml
Pharmacological properties: Pharmacodynamics. GONADOTROPINUM CHORIONICUM – human chorionic gonadotropin (hCG) obtained from the urine of pregnant women. It stimulates steroidogenesis in the gonads due to biological effects, similar to the action of human LH (the same hormone stimulates the interstitial cells). In men, hCG causes an increase in the production of testosterone, in women – increase production of estrogen and progesterone especially after ovulation. When administered hCG antibody does not say. Other ingredients: mannitol, sodium dihydrogen phosphate anhydrous, sodium hydrogen phosphate anhydrous, sodium carboxymethylcellulose.
Pharmacokinetics. The maximum concentration of hCG in the blood plasma of males reached after approximately 6 hours after a single w / o Injection, and women – about 20 h Such significant sex difference in the pharmacokinetics of the drug after the / m may be due to the greater the subcutaneous fat thickness. gluteal region in females. After the / m hCG well absorbed, its half-life is about 33 hours, about 80% decomposes predominantly in the kidney and excreted in the urine.
INDICATIONS: Women – the induction of ovulation in female infertility due to anovulation or impaired follicle maturation; for the preparation of a follicle puncture during controlled ovarian hyperstimulation in assisted reproductive technology (ART); support the luteal phase (including the period of controlled ovarian hyperstimulation with ART) using analogs of gonadotropin-releasing hormone or other means to stimulate ovulation in female infertility resulting anovulation caused by insufficient activity of endogenous estrogens (ovarian failure I group according to the WHO classification) .
The man – hypogonadotropic hypogonadism; reduction in fertility associated with idiopathic disspermiey; delayed sexual development in boys, due to lack of gonadotrophic pituitary function; cryptorchidism, unconditioned anatomical occlusion.
APPLICATIONS: rr GONADOTROPINUM CHORIONICUM, obtained by adding a solvent to the lyophilized active substance administered / m slowly.As initiated ampoule can not be re-sealed so as to further ensure sterility of the contents, the p-p should be used immediately after preparation.
The dosage for women . Ovulation induction or preparation of follicles for puncture – GONADOTROPINUM CHORIONICUM usually impose a single dose of 3000-10 000 IU.
Support luteal phase – 2-3 consecutive injections GONADOTROPINUM CHORIONICUM in a dose of 1000-3000 IU each for 9 days after ovulation and embryo transfer (for example at 3, 6 and 9 days after ovulation stimulated).
The dosage for men
These dosing regimens are only approximate and should be adjusted individually according to the relevant response to treatment.
Hypogonadotropic hypogonadism – GONADOTROPINUM CHORIONICUM appoint 1000-2000 IU 2-3 times a week.
In male infertility due to lack of spermatogenesis – GONADOTROPINUM CHORIONICUM can assign combines with FSH daily or 2-3 times a week for at least 3 months to improve spermatogenesis. For the period of treatment is necessary to temporarily lift the testosterone replacement therapy drugs. Sometimes, to maintain the achieved improvement is sufficient to introduce only hCG.
Delayed puberty – GONADOTROPINUM CHORIONICUM used in dose of 1500 IU 2-3 times a week for at least 6 months.
Cryptorchidism – a drug prescribed to children under the age of 2 years, 250 IU, 2 times a week for 6 months; under 6 years of 500-1000 IU 2 times a week for 6 months; over the age of 6 years – 1500 IU 2 times a week for 6 months; if necessary, the treatment may be repeated.
Contraindications hypersensitivity to human gonadotropins or to any component of the drug; the presence or suspicion of androgen-dependent tumor (prostate carcinoma or breast cancer in men). The presence of uncorrected endocrinopathies (hypothyroidism, adrenal gnedostatochnost, hyperprolactinemia). Cancer of the ovary, fallopian tubes
SIDE EFFECTS : at the injection site may be bruising, pain, redness, swelling and itching; sometimes – allergic reactions, mainly in the form of skin rashes and pain at the injection site, much less – a generalized rash and fever.
Women . Unwanted ovarian hyperstimulation, ovarian hyperstimulation syndrome. Clinical symptoms of small ovarian hyperstimulation syndrome are rasstroysstva gastrointestinal tract (abdominal pain, nausea, diarrhea), chest pain, mild to moderate ovarian enlargement or ovarian cysts.Sometimes develop severe ovarian hyperstimulation syndrome, which can be life-threatening. It is characterized by the appearance of large ovarian cysts (prone to rupture), development of ascites, weight gain, occurrence of hydrothorax and thromboembolic events.
In men. Sometimes, after the drug in high doses may occur and sodium water retention due to increased production of androgens. In some cases, treatment of hCG may be the cause of gynecomastia, the proliferative changes in the prostate gland. As a result – an increase in testosterone levels induced by the drug hCG, a possible increase of the penis and an erection. Hypersensitivity nipple mammary glands, testes increase in the inguinal canal.Very rarely possible to change the behavior of a comparable note that during the first phase of puberty.
SPECIAL INSTRUCTIONS : For women. When pregnancy began after ovulation induction gonadotropin drugs increases the risk of multiple pregnancy; after adjuvant hormone therapy – the risk of miscarriage; the pathology of the pipe – the risk of ectopic pregnancy (which is why it is important using ultrasound to confirm the presence of an intrauterine pregnancy). It is also necessary to exclude the presence of uncontrolled negonadnoy endocrinopathy (e.g. dysfunction of the thyroid, adrenal or pituitary).
Unwanted ovarian hyperstimulation. In the treatment of female infertility caused by anovulation or impaired follicle maturation, prior administration of the preparation of FSH may lead to unwanted ovarian hyperstimulation. Therefore prior to treatment menotropinom and at regular intervals during the period of this therapy should be carried ultrasound for the evaluation of follicular development, and to determine the level of estradiol in the blood. With the development of a large number of follicles estradiol level may rise rapidly (e.g. 2 times for 2-3 days). The diagnosis of unwanted ovarian hyperstimulation may be confirmed by ultrasound. In this case, you should immediately remove the drug, containing FSH, as there is a risk of inducing multiple ovulations and ovarian hyperstimulation syndrome. This is especially important in the treatment of patients with polycystic ovaries. Clinical symptoms of small ovarian hyperstimulation syndrome are gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight enlargement of the ovaries or ovarian cysts. In rare cases, there is a severe form of ovarian hyperstimulation syndrome, which can be life-threatening and the patient is characterized by the development of large ovarian cysts (prone to rupture), ascites, weight gain, often hydrothorax and sometimes – thromboembolic complications.
In men . Treatment of hCG leads to increased androgen production so patients with latent or overt cardiac failure, renal dysfunction, elevated blood pressure, epilepsy or migraine (including patients with this pathology was detected in the past) should be under constant medical supervision, because sometimes the production increase of androgens can cause deterioration or recurrence of the disease. In order to avoid premature epiphyseal or sexual development of hCG should be used with caution in boys during puberty. It is necessary to carefully monitor the maturation of the musculoskeletal system.
During pregnancy and breastfeeding. GONADOTROPINUM CHORIONICUM can not be used during breastfeeding. During pregnancy, the drug can be administered for luteal phase support.
OVERDOSE : hCG toxicity is very low. Symptoms of acute parenteral overdose are not known. Women may develop ovarian hyperstimulation to increase their size.
STORAGE CONDITIONS : in the dark place at a temperature of 2-15 ° C.
steriods for sale ganabol steroid buy horse steroids